细胞因子信号抑制物-3在脂肪酸β氧化中的作用
|
摘要
肥胖症问题越来越受到世界关注,同时它还伴随发生心血管疾病和脂质代谢失常等疾病。通常肥胖患者血液内都呈现高水平leptin, leptin的抵抗是造成肥胖症的关键诱因之一,而细胞内多余的SOCS3又是造成leptin抵抗的主要原因。
细胞负反馈调控因子SOCS蛋白参与细胞内各种信号通路的调控,SOCS1-SOCS7以及CIS这八个蛋白组成了SOCS3家族。通过对它们氨基酸序列比对发现：它们均包含一个SH2结构域和一个C端较保守的SOCS-box功能区域,这两个功能性结构域对SOCS家族成员十分重要,它们是SOCS蛋白调控细胞内各种信号通路的主要功能区域。
SOCS3是一个重要的负反馈调节蛋白,它参与IL-6、leptin、促红细胞生成素和胰岛素等信号途径的调控。SOCS3蛋白能够通过自身的SH2结构与JAK家族的酪氨酸激酶结合直接抑制其酶活性或者SOCS3结合信号分子将其带入蛋白酶降解途径,从而抑制细胞内的信号通路。leptin是一个脂肪组织分泌的细胞因子,其功能是维持体内能量平衡和降低食物摄取量,它通过血脑屏障与位于下丘脑的受(体瘦素受体,简称OB-R)结合,引起STAT1和STAT3活化。磷酸化的STAT3能够诱导SOCS3基因表达。通常肥胖症患者血液中的leptin含量高,能长时间持续的刺激OB-R使得细胞内SOCS3过表达。SOCS3作为leptin信号通路负反馈机制,过剩的SOCS3和JAK结合直接抑制酶的活性,并且将JAK信号分子带入蛋白酶降解途径。SOCS3的基因敲除小鼠用高脂饲料喂养后,其体重和脂肪含量减轻,因此,SOCS3可能在能量代谢和脂肪酸氧化中扮演重要角色。然而,SOCS3调控目标蛋白的机制还研究得不够透彻。
为了进一步研究SOCS3蛋白抑制细胞因子信号转导的机制和其潜在的肥胖症治疗功能,我们以表达纯化的HIS-SOCS3为诱饵蛋白利用噬菌体展示技术从人肝的cDNA文库中筛选能与其相互作用的短肽。通过对筛选出来的一条短肽的序列RGGVVTSNPLGF分析,我们发现该短肽序列与编码VLCAD蛋白C末端644-655位的12个氨基酸序列相同,暗示SOCS3与VLCAD艮可能具有相互作用。为了证明这一点,我们用酵母双杂交系统构建了两个表达质粒pGBKT7-SOCS3和pGADT7-VLCAD,共转化酵母菌AH109,我们发现,重组菌落能够在-Trp-Leu-His的平板上生长,β半乳糖苷酶显色实验阳性。实验结果充分证明SOCS3蛋白能与VLCAD蛋白相互作用。我们首次发现了超长链乙酰辅酶A (VLCAD)是一个重要的SOCS3结合蛋白。
乙酰辅酶A脱氢酶属于线粒体中的黄素酶,具有催化脂肪酸β氧化起始反应的活性。细胞中存在四种不同乙酰辅酶A脱氢酶：短链乙酰辅酶脱氢酶(SCAD),中链乙酰辅酶脱氢酶(MCAD),长链乙酰辅酶脱氢酶(LCAD)和超长链乙酰辅酶脱氢酶(VLCAD)位于462位的GLU被认为是酶的重要活性中心。其中以VLCAD活性最强。
通过氨基酸序列比较发现,这四种乙酰辅酶A脱氢酶的C-端都含有加长的25KD尾巴。当棕榈酸乙酰A作为酶的底物时,VLCAD的活性比LCAD高10倍。目前对这条25KD的特殊序列的功能还不了解。
进一步,我们还通过体外GST pull-down实验和体内免疫共沉淀实验,验证了SOCS3蛋白与VLCAD蛋白的相互作用。为了深入研究这种相互作用的功能区,我们又将VLCADC端含有220个氨基酸的extra-peptide构建至真核表达载体pCMV-HA上,转染至小鼠巨噬细胞RAW264.7,用LPS刺激细胞,刺激时间依次为1h,2h,4h和8h,细胞裂解后Western blot检测蛋白的表达情况。我们发现,由于LPS的刺激诱导了SOCS3蛋白的表达,同时,相应的减少了VLCAD的表达,这意味着VLCAD的C端部分能够被SOCS3蛋白降解。其降解机制估计是由于SOCS3蛋白能够结合VLCADC端25KD的尾巴,并且将其带入到蛋白酶体降解途径。
为了证明SOCS3蛋白参与VLCAD的降解而带来的减肥功效,我们合成了VLCADC末端的12个氨基酸短肽,将其从腹腔注射至昆明小鼠体内,每三天加强注射一次并称量小鼠体重,24天后我们观察到注射PBS的空白对照小鼠体重增加最为显著,注射随机十肽的对照小鼠体重增加次之,而注射VLCAD特异性12短肽的小鼠体重增加最为缓慢。同时我们还检测小鼠血液中的总甘油三脂(TG)和总胆固醇
(TC)含量作为减肥的重要生理指标,我们发现注射VLCAD特异性12短肽小鼠的TG和TC含量比对照小鼠显著降低,具有一定的减肥作用。减肥功能的机制可能是由于合成的特异性12短肽在小鼠体内竞争性结合了SOCS3蛋白,从而释放更多的VLCAD酶分子,VLCAD是脂肪酸β氧化反应第一步的限速酶,因此加快了体内更多脂肪酸的代谢速度。而降低了老鼠的体重。综合以上结果,我们的研究首次证明了SOCS3蛋白与超长链乙酰辅酶A相互结合,结合的功能区是VLCAD-C末端12氨基酸。随着SOCS3与VLCAD-C末端25KD尾巴的结合而将VLCAD带入泛素化降解途径,影响VLCAD的正常功能而降低机体脂肪酸代谢。这可能是解释为什么肥胖症患者脂肪酸代谢缓慢的重要原因之一。我们认为,SOCS3是脂肪β氧化反应代谢重要负调控因子和治疗肥胖症潜在的药物作用位点。合成的VLCAD-C末端12氨基酸短肽也有可能成为治疗肥胖症的重要靶标药物。
Obesity is a major global public health issue that has drawn the attention of physicians and other health care professionals; meanwhile it also has an association with cardiovascular disease, metabolic disorders and other diseases. The high level of leptin is reversely existed in the blood of obese patients. Leptin resistance as a key factor results in obesity. The current studies demonstrated that leptin-resistance is mainly attributed to the surplus SOCS3in the cell.
Suppressor of cytokine signaling(SOCS)proteins have been involved in cytokine signaling as a family of negative regulators. The SOCS family comprises eight proteins, including SOCS1-SOCS7and CIS. Based on their amino acid sequence alignment, the result indicates that all the members of family contain a central SH2domain and a conserved C-terminal SOCS box. Those domains contain very important function, which has involved in the regulation of cytokine signaling by different mechanisms.
SOCS3is thought as an important negative regulator of IL-6, leptin, erythropoietin and insulin signaling pathways. SOCS3protein binds to the activation loop of Jak family tyrosine kinases and directly inhibits their kinase activity through its SH2domain and kinase inhibitory region. SOCS3also can draw the activated signaling proteins into the the ubiquitination pathway for proteasomal degradation to inhibit signal pathway in cell. Leptin as a polypeptide, a product of the Ob gene, is an endocrine signal released from adipocytes to regulate body energy balance and reduce food intake. It can cross the blood-brain barrier to bind with the leptin receptor (OB-R) in the hypothalamus. Leptin induces activation of STAT1and STAT3through binding with its receptor OB-R. The phosphorylation of STAT3activates the expression of SOCS3gene. The high level of leptin is reversely existed in the blood of obese patients. The OB-R is continuously stimulated by the high level of leptin in the obese body, leading to the overexpresion of SOCS3in the cell. SOCS3as the negative feedback regulator of leptin signaling pathway not only directly bind to the JAK and inhibit the activity of enzyme, but also draw JAK into the ubiquitination pathway for proteasomal degradation. The experiment demonstrated that the fat content of mice with SOCS3gene knock out is lower than the mice without the SOCS3gene knock out after feeding the high fat diet. SOCS3may play an important part in the fatty acid oxidation and energe metabolism. The regulation mechanism of of SOCS3has not studied thoroughtly.
To further investigate potential treatment of obesity and the suppression cytokine signal transduction mechanism of SOCS3protein, we developed T7select phage display system with purified HIS-SOCS3as bait to screen a human liver cDNA library in order to search for interaction of short peptides. After screening and sequencing analysis, we found that phage-presenting peptide RGGVVTSNPLGF show significant binding to SOCS3. The peptide sequence was similar to the sequence of amino acids644-655of C-terminal extra-polypeptide of very-long-chain acyl-CoA dehydrogenase (VLCAD). The result imply that SOCS3may interact with VLCAD. To further to prove it, We also carried out yeast two hybrid experiments to testify the interaction between SOCS3protein and VLCAD. First of all, we construct two pGBKT7-SOCS3and pGADT7-VLCAD expression plasmid for yeast hybrid system. Then, the yeast strain AH109which was transformed with pGBKT7-SOCS3and pGADT7-VLCAD expression plasmid grows on the-Trp-Leu-His plate. The β-galactosidase activity was measured. The result of experiment is positive. It indicated that SOCS3protein can bind with VLCAD in the yeast system. We identified protein VLCAD as a potential SOCS3interacting protein at the first time.
The acyl-CoA dehydrogenases are mitochondrial flavoenzymes that catalyze the initial step in fatty acid β-oxidation. This reaction involves the2,3-dehydrogenation of acyl-CoA thioesters with formation of the trans-2-enoyl-CoA product. Four distinct acyl-CoA dehydrogenases, SCAD, MCAD, LCAD and VLCAD have been identified in cell. The location of462GLU is considered as an important catalytic residue, meanwhile VLCAD shows the highest central activity of enzyme in four distinct acyl-CoA dehydrogenases.
Based on their amino acid sequence alignment, the sequence of VLCAD has the high similarity to SCAD (60%), MACD (48%), and LCAD (35%). VLCAD is a unique dehydrogenase in that it contains about25kDa of extra polypeptide at the carboxyl-terminal side compared to the other dehydrogenases, has a10-fold higher specific activity than that of LCAD toward palmitoyl-CoA as substrate. At present, the function of the special25KDa of extra polypeptide is still unknown.
To confirm the interaction between SOCS3and VLCAD, we performed in vitro GST pull-down experiment and in vivo immunoprecipitation. In order to further research on the interaction of region, we construct pCMA-VLCAD-C-terminal extra polypeptide eukaryotic expression plasmid, which transfects into Mouse macrophages RAW264.7cells. After36h of culture, the cells were stimulated with LPS. Then, whole-cell lysates were immunoblotted with antibodies to HA-tag at1,2,4,8h after LPS stimulation. Our studies find that LPS definitely stimulates the SOCS3expression, meanwhile the reversely reduced extra-polypeptide expression was detected by immunoblotting with antibodies to HA-tag as the increasing expression of SOCS3under LPS stimulation. The degradation mechanism of VLCAD C-terminal probably is that extra-polypeptides that SOCS3-targeted25KDa VLCAD C-terminal extra-polypeptide entered the ubiquitination pathway for proteasomal degradation
Competitive binding inhibition of plus SOCS3protein in cell may be a potential treatment of obesity. Then, the12aa peptide of VLCAD C-terminal was synthesized and injected in the Kun Ming mice. The PBS and a scrambled12aa peptide were used as control. The weight of mice was measured every three days. After one month, the gain in weight of mice injected with12aa peptide of VLCAD C-terminal increased slowest. We also measure the total triglycerides (TG) and total cholesterol (TC) in the mice blood as important physiological index. Finally, we identified that TG and TC content of mice injected with specific VLCAD C-terminal12peptides are lower than the control group. Certainly, VLCAD C-terminal12peptides has the effect on the anti-obesity. The mechanism of anti-obesity is that the binding site of SOCS3is possibly competitive occupied by the synthetic VLCAD C-terminal12peptides, to prevent the interaction of SOCS3and VLCAD. Releasing more VLCAD involvement in fatty acid β-oxidation led to increasing weight loss and strengthening the fat metabolism. VLCAD is a rate-limiting enzyme in the long-chain fatty acid P-oxidation system.
In conclusion, we for the first time demonstrated that SOCS3protein can interact with VLCAD, meanwhile the sequence of amino acids644-655of C-terminal extra-polypeptide of VLCAD as the binding area has a specific binding to SOCS3, which mediates the ubiquitination pathway for proteasomal degradation of25KDa VLCAD C-terminal extra-polypeptide and make the VLCAD disfunctional. These results explain why the fatty acid oxidation is slower in the obese body in the mechanism. SOCS3is an important factor for lipid metabolism and a potential drug-target for treatment of widespread obesity. This small peptide may potentially be useful therapeutics for the treatment of obesity.
细胞负反馈调控因子SOCS蛋白参与细胞内各种信号通路的调控,SOCS1-SOCS7以及CIS这八个蛋白组成了SOCS3家族。通过对它们氨基酸序列比对发现：它们均包含一个SH2结构域和一个C端较保守的SOCS-box功能区域,这两个功能性结构域对SOCS家族成员十分重要,它们是SOCS蛋白调控细胞内各种信号通路的主要功能区域。
SOCS3是一个重要的负反馈调节蛋白,它参与IL-6、leptin、促红细胞生成素和胰岛素等信号途径的调控。SOCS3蛋白能够通过自身的SH2结构与JAK家族的酪氨酸激酶结合直接抑制其酶活性或者SOCS3结合信号分子将其带入蛋白酶降解途径,从而抑制细胞内的信号通路。leptin是一个脂肪组织分泌的细胞因子,其功能是维持体内能量平衡和降低食物摄取量,它通过血脑屏障与位于下丘脑的受(体瘦素受体,简称OB-R)结合,引起STAT1和STAT3活化。磷酸化的STAT3能够诱导SOCS3基因表达。通常肥胖症患者血液中的leptin含量高,能长时间持续的刺激OB-R使得细胞内SOCS3过表达。SOCS3作为leptin信号通路负反馈机制,过剩的SOCS3和JAK结合直接抑制酶的活性,并且将JAK信号分子带入蛋白酶降解途径。SOCS3的基因敲除小鼠用高脂饲料喂养后,其体重和脂肪含量减轻,因此,SOCS3可能在能量代谢和脂肪酸氧化中扮演重要角色。然而,SOCS3调控目标蛋白的机制还研究得不够透彻。
为了进一步研究SOCS3蛋白抑制细胞因子信号转导的机制和其潜在的肥胖症治疗功能,我们以表达纯化的HIS-SOCS3为诱饵蛋白利用噬菌体展示技术从人肝的cDNA文库中筛选能与其相互作用的短肽。通过对筛选出来的一条短肽的序列RGGVVTSNPLGF分析,我们发现该短肽序列与编码VLCAD蛋白C末端644-655位的12个氨基酸序列相同,暗示SOCS3与VLCAD艮可能具有相互作用。为了证明这一点,我们用酵母双杂交系统构建了两个表达质粒pGBKT7-SOCS3和pGADT7-VLCAD,共转化酵母菌AH109,我们发现,重组菌落能够在-Trp-Leu-His的平板上生长,β半乳糖苷酶显色实验阳性。实验结果充分证明SOCS3蛋白能与VLCAD蛋白相互作用。我们首次发现了超长链乙酰辅酶A (VLCAD)是一个重要的SOCS3结合蛋白。
乙酰辅酶A脱氢酶属于线粒体中的黄素酶,具有催化脂肪酸β氧化起始反应的活性。细胞中存在四种不同乙酰辅酶A脱氢酶：短链乙酰辅酶脱氢酶(SCAD),中链乙酰辅酶脱氢酶(MCAD),长链乙酰辅酶脱氢酶(LCAD)和超长链乙酰辅酶脱氢酶(VLCAD)位于462位的GLU被认为是酶的重要活性中心。其中以VLCAD活性最强。
通过氨基酸序列比较发现,这四种乙酰辅酶A脱氢酶的C-端都含有加长的25KD尾巴。当棕榈酸乙酰A作为酶的底物时,VLCAD的活性比LCAD高10倍。目前对这条25KD的特殊序列的功能还不了解。
进一步,我们还通过体外GST pull-down实验和体内免疫共沉淀实验,验证了SOCS3蛋白与VLCAD蛋白的相互作用。为了深入研究这种相互作用的功能区,我们又将VLCADC端含有220个氨基酸的extra-peptide构建至真核表达载体pCMV-HA上,转染至小鼠巨噬细胞RAW264.7,用LPS刺激细胞,刺激时间依次为1h,2h,4h和8h,细胞裂解后Western blot检测蛋白的表达情况。我们发现,由于LPS的刺激诱导了SOCS3蛋白的表达,同时,相应的减少了VLCAD的表达,这意味着VLCAD的C端部分能够被SOCS3蛋白降解。其降解机制估计是由于SOCS3蛋白能够结合VLCADC端25KD的尾巴,并且将其带入到蛋白酶体降解途径。
为了证明SOCS3蛋白参与VLCAD的降解而带来的减肥功效,我们合成了VLCADC末端的12个氨基酸短肽,将其从腹腔注射至昆明小鼠体内,每三天加强注射一次并称量小鼠体重,24天后我们观察到注射PBS的空白对照小鼠体重增加最为显著,注射随机十肽的对照小鼠体重增加次之,而注射VLCAD特异性12短肽的小鼠体重增加最为缓慢。同时我们还检测小鼠血液中的总甘油三脂(TG)和总胆固醇
(TC)含量作为减肥的重要生理指标,我们发现注射VLCAD特异性12短肽小鼠的TG和TC含量比对照小鼠显著降低,具有一定的减肥作用。减肥功能的机制可能是由于合成的特异性12短肽在小鼠体内竞争性结合了SOCS3蛋白,从而释放更多的VLCAD酶分子,VLCAD是脂肪酸β氧化反应第一步的限速酶,因此加快了体内更多脂肪酸的代谢速度。而降低了老鼠的体重。综合以上结果,我们的研究首次证明了SOCS3蛋白与超长链乙酰辅酶A相互结合,结合的功能区是VLCAD-C末端12氨基酸。随着SOCS3与VLCAD-C末端25KD尾巴的结合而将VLCAD带入泛素化降解途径,影响VLCAD的正常功能而降低机体脂肪酸代谢。这可能是解释为什么肥胖症患者脂肪酸代谢缓慢的重要原因之一。我们认为,SOCS3是脂肪β氧化反应代谢重要负调控因子和治疗肥胖症潜在的药物作用位点。合成的VLCAD-C末端12氨基酸短肽也有可能成为治疗肥胖症的重要靶标药物。
Obesity is a major global public health issue that has drawn the attention of physicians and other health care professionals; meanwhile it also has an association with cardiovascular disease, metabolic disorders and other diseases. The high level of leptin is reversely existed in the blood of obese patients. Leptin resistance as a key factor results in obesity. The current studies demonstrated that leptin-resistance is mainly attributed to the surplus SOCS3in the cell.
Suppressor of cytokine signaling(SOCS)proteins have been involved in cytokine signaling as a family of negative regulators. The SOCS family comprises eight proteins, including SOCS1-SOCS7and CIS. Based on their amino acid sequence alignment, the result indicates that all the members of family contain a central SH2domain and a conserved C-terminal SOCS box. Those domains contain very important function, which has involved in the regulation of cytokine signaling by different mechanisms.
SOCS3is thought as an important negative regulator of IL-6, leptin, erythropoietin and insulin signaling pathways. SOCS3protein binds to the activation loop of Jak family tyrosine kinases and directly inhibits their kinase activity through its SH2domain and kinase inhibitory region. SOCS3also can draw the activated signaling proteins into the the ubiquitination pathway for proteasomal degradation to inhibit signal pathway in cell. Leptin as a polypeptide, a product of the Ob gene, is an endocrine signal released from adipocytes to regulate body energy balance and reduce food intake. It can cross the blood-brain barrier to bind with the leptin receptor (OB-R) in the hypothalamus. Leptin induces activation of STAT1and STAT3through binding with its receptor OB-R. The phosphorylation of STAT3activates the expression of SOCS3gene. The high level of leptin is reversely existed in the blood of obese patients. The OB-R is continuously stimulated by the high level of leptin in the obese body, leading to the overexpresion of SOCS3in the cell. SOCS3as the negative feedback regulator of leptin signaling pathway not only directly bind to the JAK and inhibit the activity of enzyme, but also draw JAK into the ubiquitination pathway for proteasomal degradation. The experiment demonstrated that the fat content of mice with SOCS3gene knock out is lower than the mice without the SOCS3gene knock out after feeding the high fat diet. SOCS3may play an important part in the fatty acid oxidation and energe metabolism. The regulation mechanism of of SOCS3has not studied thoroughtly.
To further investigate potential treatment of obesity and the suppression cytokine signal transduction mechanism of SOCS3protein, we developed T7select phage display system with purified HIS-SOCS3as bait to screen a human liver cDNA library in order to search for interaction of short peptides. After screening and sequencing analysis, we found that phage-presenting peptide RGGVVTSNPLGF show significant binding to SOCS3. The peptide sequence was similar to the sequence of amino acids644-655of C-terminal extra-polypeptide of very-long-chain acyl-CoA dehydrogenase (VLCAD). The result imply that SOCS3may interact with VLCAD. To further to prove it, We also carried out yeast two hybrid experiments to testify the interaction between SOCS3protein and VLCAD. First of all, we construct two pGBKT7-SOCS3and pGADT7-VLCAD expression plasmid for yeast hybrid system. Then, the yeast strain AH109which was transformed with pGBKT7-SOCS3and pGADT7-VLCAD expression plasmid grows on the-Trp-Leu-His plate. The β-galactosidase activity was measured. The result of experiment is positive. It indicated that SOCS3protein can bind with VLCAD in the yeast system. We identified protein VLCAD as a potential SOCS3interacting protein at the first time.
The acyl-CoA dehydrogenases are mitochondrial flavoenzymes that catalyze the initial step in fatty acid β-oxidation. This reaction involves the2,3-dehydrogenation of acyl-CoA thioesters with formation of the trans-2-enoyl-CoA product. Four distinct acyl-CoA dehydrogenases, SCAD, MCAD, LCAD and VLCAD have been identified in cell. The location of462GLU is considered as an important catalytic residue, meanwhile VLCAD shows the highest central activity of enzyme in four distinct acyl-CoA dehydrogenases.
Based on their amino acid sequence alignment, the sequence of VLCAD has the high similarity to SCAD (60%), MACD (48%), and LCAD (35%). VLCAD is a unique dehydrogenase in that it contains about25kDa of extra polypeptide at the carboxyl-terminal side compared to the other dehydrogenases, has a10-fold higher specific activity than that of LCAD toward palmitoyl-CoA as substrate. At present, the function of the special25KDa of extra polypeptide is still unknown.
To confirm the interaction between SOCS3and VLCAD, we performed in vitro GST pull-down experiment and in vivo immunoprecipitation. In order to further research on the interaction of region, we construct pCMA-VLCAD-C-terminal extra polypeptide eukaryotic expression plasmid, which transfects into Mouse macrophages RAW264.7cells. After36h of culture, the cells were stimulated with LPS. Then, whole-cell lysates were immunoblotted with antibodies to HA-tag at1,2,4,8h after LPS stimulation. Our studies find that LPS definitely stimulates the SOCS3expression, meanwhile the reversely reduced extra-polypeptide expression was detected by immunoblotting with antibodies to HA-tag as the increasing expression of SOCS3under LPS stimulation. The degradation mechanism of VLCAD C-terminal probably is that extra-polypeptides that SOCS3-targeted25KDa VLCAD C-terminal extra-polypeptide entered the ubiquitination pathway for proteasomal degradation
Competitive binding inhibition of plus SOCS3protein in cell may be a potential treatment of obesity. Then, the12aa peptide of VLCAD C-terminal was synthesized and injected in the Kun Ming mice. The PBS and a scrambled12aa peptide were used as control. The weight of mice was measured every three days. After one month, the gain in weight of mice injected with12aa peptide of VLCAD C-terminal increased slowest. We also measure the total triglycerides (TG) and total cholesterol (TC) in the mice blood as important physiological index. Finally, we identified that TG and TC content of mice injected with specific VLCAD C-terminal12peptides are lower than the control group. Certainly, VLCAD C-terminal12peptides has the effect on the anti-obesity. The mechanism of anti-obesity is that the binding site of SOCS3is possibly competitive occupied by the synthetic VLCAD C-terminal12peptides, to prevent the interaction of SOCS3and VLCAD. Releasing more VLCAD involvement in fatty acid β-oxidation led to increasing weight loss and strengthening the fat metabolism. VLCAD is a rate-limiting enzyme in the long-chain fatty acid P-oxidation system.
In conclusion, we for the first time demonstrated that SOCS3protein can interact with VLCAD, meanwhile the sequence of amino acids644-655of C-terminal extra-polypeptide of VLCAD as the binding area has a specific binding to SOCS3, which mediates the ubiquitination pathway for proteasomal degradation of25KDa VLCAD C-terminal extra-polypeptide and make the VLCAD disfunctional. These results explain why the fatty acid oxidation is slower in the obese body in the mechanism. SOCS3is an important factor for lipid metabolism and a potential drug-target for treatment of widespread obesity. This small peptide may potentially be useful therapeutics for the treatment of obesity.
引文
[1]Adams, T. E., J. A. Hansen, et al. (1998). "Growth hormone preferentially induces the rapid, transient expression of SOCS-3, a novel inhibitor of cytokine receptor signaling." J Biol Chem 273 (3):1285-7.
[2]Adams SH, Hoppel CL, Lok KH et al (2009) Plasma acylcarnitine prof iles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women, J Nutr 139:1073-1081
[3]Akiyama M,Sakai K,Ogawa M, McMillan JR,Sawamura D,Shimizu H. Novel duplication mutation in the patatin domain of adipose triglyceride lipase (PNPLA2) in neutral lipid storage disease with severe myopathy. Muscle Nerve 2007; 36:856-9.
[4]Aman, M. J. and W. J. Leonard (1997). "Cytokine signaling:cytokine-inducible signaling inhibitors." Curr Biol 7 (12):R784-8.
[5]Andresen BS, Vianey-Saban C, Bross P, et al. The mutational spectrum in very long-chain acyl-CoA dehydrogenase deficiency. J Inherit Metab Dis 1996; 19:169-72.
[6]Andresen BS, Olpin S, Poorthuis BJHM, et al. Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. Am J Hum Genet 1999; 64:478-94.
[7]Aoyama, T., M. Souri, et al. (1995). "Cloning of human very-long-chain acyl-coenzyme A dehydrogenase and molecular characterization of its deficiency in two patients." Am J Hum Genet 57 (2):273-83.
[8]Aoyama, T.,1. Ueno, et al. (1994). "Rat very-long-chain acyl-CoA dehydrogenase-a novel mitochondrial acyl-CoA dehydrogenase gene product, is a rate-limiting enzyme in long-chain fatty acid beta-oxidation system. cDNA and deduced amino acid sequence and distinct specificities of the cDNA-expressed protein. " J Biol Chem 269 (29):19088-94.
[9]Attoub, S., V. Noe, et al. (2000). "Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, rho-, and rac-dependent signaling pathways." Faseb J 14 (14):2329-38.
[10]Bado, A., S. Levasseur, et al. (1998). "The stomach is a source of leptin. " Nature 394 (6695):790-3.
[11]Baerlocher KE, Steinmann B, Aguzzi A, KraenbOl S, Roe CR, Vianey-Saban C. Short-chain acyl-CoA dehydrogenase deficiency in a 16-year-old girl with severe muscle wasting and scoliosis. J Inher Metab Dis 1997; 20:427-31.
[12]Banerjee, A., A. S. Banks, et al. (2002). "Cutting edge:Suppressor of cytokine signaling 3 inhibits activation of NFATp. " J Immunol 168 (9):4277-81.
[13]Banks, A. S., S. M. Davis, et al. (2000). "Activation of downstream signals by the long form of the leptin receptor." J Biol Chem 275 (19):14563-72.
[14]BartlettK, Eaton S (2004) Mitochondrial beta-oxidation. Eur J Biochem 271:462-469
[15]Ben Ammar A, Petit F, Alexandri N, et al. Phenotype genotype analysis in 15 patients presenting congenital myasthenic syndrome due to mutation in DOK7. J Neurol 2010; 257:754-66.
[16]Binas B, Han XX, Erol E et al (2003) A null mutation in H-FABP only partially inhibits skeletal muscle fatty acid metabolism. Am J Physiol Endocrinol Metab 285:E481-E489
[17]Bjorbaek, C., K. El-Haschimi, et al. (1999). "The role of SOCS-3 in leptin signaling and leptin resistance." J Biol Chem 274 (42):30059-65.
[18]Bjorbaek, C., J. K. Elmquist, et al. (1998). "Identification of SOCS-3 as a potential mediator of central leptin resistance. " Mol Cell 1 (4):619-25.
[19]Bjorbak, C., H. J. Lavery, et al. (2000). "SOCS3 mediates feedback inhibition of the leptin receptor via Tyr985. " J Biol Chem 275 (51):40649-57.
[20]Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J (2004) Carnitine palmitoyltransferases 1 and 2:biochemical, molecular and medical aspects. Mol Aspects Med 25:495-520
[21]Brender, C., P. Lovato, et al. (2005). "Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha. " Leukemia 19 (2) 209-13.
[22]Brivet M, Tubiana S, Boutron A, et al. Transcriptional analysis of HADHA and HADHB genes encoding the mitochondrial trifunctional protein. J Inher Metab Dis 2008; 31:35.
[23]Bruno C, Bertini E, Di Rocco M, et al. Clinical et genetic characterization of Chanarin-Dorfman syndrome. Biochem Biophys Res Commun 2008; 369:1125-8.
[24]Cacalano, N. A., D. Sanden, et al. (2001). "Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras. " Nat Cell Biol 3 (5):460-5.
[25]Campagna F, Nanni L, Quagliarini F. et al. Novel mutations in the adipose triglyceride lipase gene causing neutral lipid storage disease with myopathy. Biochem Biophys Res Commun 2008; 377:843-6.
[26]Chanarin I, Patel A, Slavin G, Wills EJ, Andrews TM. Stewart G. Neutral-lipid
[27]storage disease:a new disorder of lipid metabolism. Br Med J 1975; 1:553-b.
[28]Chegary M, te Brinke H, Ruiter JP et al (2009) Mitochondrial long chain fatty acid beta-oxidation in man and mouse. Biochim Biophys Acta 1791:806-815
[29]Cheng, F., H. W. Wang, et al. (2003). "A critical role for Stat3 signaling in immune tolerance." Immunity 19 (3):425-36.
[30]Ciechanover, A., A, Orian, et al. (2000). "Ubiquitin-mediated proteolysis: biological regulation via destruction. " Bioessays 22 (5):442-51.
[31]Corti S.Bordoni A, Ronchi D, et al. Clinical features and new molecular findings in carnitine palmitoyltransferase Ⅱ (CPTⅡ) deficiency. J Neurol Sci 2008; 266:97-103.
[32]Crespo, A., M. B. Filla, et al. (2000). "Indirect induction of suppressor of cytokine signalling-1 in macrophages stimulated with bacterial lipopolysaccharide:partial role of autocrine/paracrine interferon-alpha/beta." Biochem J 349 (Pt 1):99-104.
[33]Croker, B. A., D. L. Krebs, et al. (2003). "SOCS3 negatively regulates IL-6 signaling in vivo." Nat Immunol 4 (6):540-5.
[34]Czech,M. P. and S. Corvera(1999). "Signaling mechanisms that regulate glucose transport." J Biol Chem 274 (4):1865-8.
[35]Dakin HD (1908) Comparative studies of the mode of oxidation of phenyl derivatives of fatty acids by the animal organism and by hydrogen peroxide, j Biol Chem 4:419-435
[36]Das AM, Fingerhut R, Wanders RJ, Ullrich K. Secondary respiratory chain defect in a boy with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency:possible diagnostic pitfalls. Eur J Pediatr 2000; 159:243-6.
[37]Dariusz Moczulski, Lwona Majak, et al. (2009). " An overview of β-oxidation Disorders". Postepy Hig Med Dosw 63:266-277.
[38]De Souza, D., L. j. Fabri, et al. (2002). "SH2 domains from suppressor of cytokine signaling-3 and protein tyrosine phosphatase SHP-2 have similar binding specificities." Biochemistry 41 (29):9229-36.
[39]Di Donato S, Taroni F. Disorders of lipid metabolism. In:Engel A, editor. Myology. New York:McGraw-Hill Professional Publishing; 2004. p.1587-615.
[40]Dickensheets, H. L., C. Venkataraman, et al. (1999). "Interferons inhibit activation of STAT6 by interleukin 4 in human monocytes by inducing SOCS-1 gene expression." Proc Natl Acad Sci U S A 96 (19):10800-5.
[41]DiMauro S, Melis-DiMauro PM. Muscle carnitine palmitoyltransferase deficiency and myoglobinuria. Science 1973; 182:929-31.
[42]DiMauro S. Papadimitriou A. Carnitine palmitoyl transferase deficiency. In: Engel AG, Banker BQ, editors. Myology. New York:McGraw-Hill; 1986. P.1687-708.
[43]Doege H, Stahl A (2006) Protein-mediated fatty acid uptake:novel insights from in vivo models. Physiology (Bethesda) 21:259-268
[44]Doege H, Baillie RA, Ortegon AM et al (2006) Targeted deletion of FATP5 reveals multiple functions in liver metabolism:alterations in hepatic lipid homeostasis. Gastroenterology 130:1245-1258
[45]Drynan L, Quant PA, Zammit VA (1996) Flux control exerted by mitochondrial outer membrane carnitine palmitoyltransferase over beta-oxidation, ketogenesis and tricarboxylic acid cycle activity in hepatocytes isolated from rats in different metabolic states. Biochem J 317 (Pt 3):791-795
[46]Dunn, S. L., M. Bjornholm, et al. (2005). "Feedback inhibition of leptin receptor/Jak2 signaling via Tyrl138 of the leptin receptor and suppressor of cytokine signaling 3." Mol Endocrinol 19 (4):925-38.
[47]Egwuagu, C. E., C. R. Yu, et al. (2002). "Suppressors of cytokine signaling proteins are differentially expressed in Thl and Th2 cells:implications for Th cell lineage commitment and maintenance." J Immunol 168 (7):3181-7.
[48]Emanuelli, B., M. Glondu, et al. (2004). "The potential role of SOCS-3 in the interleukin-lbeta-induced desensitization of insulin signaling in pancreatic beta-cells." Diabetes 53 Suppl 3:S97-S103.
[49]Emanuelli, B., P. Peraldi, et al. (2000). "SOCS-3 is an insulin-induced negative regulator of insulin signaling." J Biol Chem 275 (21):15985-91.
[50]Endo, T. A., M. Masuhara, et al. (1997). "A new protein containing an SH2 domain that inhibits JAK kinases. " Nature 387 (6636):921-4.
[51]Engel AC, Angelini C. Carnitine deficiency of human skeletal muscle with associated lipid storage myopathy. A new syndrome. Science 1973; 179:899-902.
[52]Ensenauer R, He M, Willard JM et al (2005) Human acyl-CoA dehydrogenase-9 plays a novel role in the mitochondrial betaoxidation of unsaturated fatty acids. J Biol Chem 280:32309-32316
[53]Erol E, Kumar LS, Cline GW, Shulman GI, Kelly DP, Binas B (2004) Liver fatty acid binding protein is required for high rates of hepatic fatty acid oxidation but not for the action of PPARa lpha in fasting mice. FASEB J 18:347-349
[54]Fischer J, Lefevre C, Morava E, et al. The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy. Nat Genet 2007; 39:28-30.
[55]Forman BM, Chen J, Evans RM (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 94:4312-4317
[56]Fujimoto, M. and T. Naka (2003). "Regulation of cytokine signaling by SOCS family molecules." Trends Immunol 24 (12):659-66.
[57]Fritz IB (1955) The effect of muscle extracts on the oxidation of palmitic acid by liver slices and homogenates. Acta Physiol Scand 34:367-385
[58]Fritz IB, McEwen B(1959) Effects of carnitine on fatty-acid oxidation by muscle. Science 129:334-335
[59]Furuta S, Miyazawa S, Hashimoto T (1981) Purification and properties of rat liver acyl-CoA dehydrogenases and electron transfer flavoprotein. J Biochem 90:1739-1750
[60]Gimeno RE, OrtegonAM, Patel S et al (2003) Characterization of a heartspec if ic fatty acid transport protein. J Biol Chem 278:16039-16044
[61]Giordanetto, F. and R. T. Kroemer (2003). "A three-dimensional model of Suppressor Of Cytokine Signalling 1 (SOCS-1)." Protein Eng 16 (2):115-24.
[62]Glatz JF, Bonen A, Ouwens DM, Luiken JJ (2006) Regulation of sarcolemmal transport of substrates in the healthy and diseased heart. Cardiovasc Drugs Ther 20:471-476
[63]Goodpaster BH, Thaete FL, Simoneau JA, Kelley DE. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 1997; 46:1579-85.
[64]Gregersen N, Bross P, Andresen BS:Genetic defects in fatty acid beta-oxidation and acyl-CoA dehydrogenases. Molecular pathogenesis and genotype-phenotype relationships. Eur JBiochem 2004,271:470-482.
[65]Gregersen N, Andresen BS, Pedersen CB, Olsen RK, Corydon TJ, Bross P. Mitochondrial fatty acid oxidation defects-remaining challenges. J Inherit Metab Dis 2008; 31:643-57.
[66]Gylvin, T., R. Nolsoe, et al. (2004). "Mutation analysis of suppressor of cytokine signalling 3, a candidate gene in Type 1 diabetes and insulin sensitivity." Diabetologia 47 (7):1273-7.
[67]Hashimoto, C., K. L. Hudson, et al. (1988). "The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein." Cell 52 (2):269-79.
[68]He,B.,L. You, et al. (2003). "SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer." Proc Natl Acad Sci U S A 100 (24):14133-8.
[69]He, B., L. You, et al. (2004). "Activity of the suppressor of cytokine signal ing-3 promoter in human non-small-cell lung cancer." Clin Lung Cancer 5 (6):366-70.
[70]Helge JW, Stallknecht B, Richter EA, Galbo H, Kiens B (2007) Muscle metabolism during graded quadriceps exercise in man. J Physiol 581:1247-1258
[71]Hershko, A., A. Ciechanover, et al. (2000). "Basic Medical Research Award. The ubiquitin system." Nat Med 6 (10):1073-81.
[72]Hilton, D. J., R. T. Richardson, et al. (1998). "Twenty proteins containing a C-terminal SOCS box form five structural classes." Proc Natl Acad Sci U S A 95 (1):114-9.
[73]Hirano, T., T. Taga, et al. (1985). "Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). " Proc Natl Acad Sci U S A 82 (16):5490-4.
[74]Holler, D. and I. Dikic(2004). "Receptor endocytosis via ubiquitin-dependent and -independent pathways." Biochem Pharmacol 67 (6):1013-7.
[75]Hortner, M., U. Nielsch, et al. (2002). "A new high affinity binding site for suppressor of cytokine signal ing-3 on the erythropoietin receptor. " Eur J Biochem 269 (10):2516-26.
[76]Houseknecht, K. L., C. A. Baile, et al. (1998). "The biology of leptin:a review." J Anim Sci 76 (5):1405-20.
[77]Houseknecht, K. L., C. S. Mantzoros, et al. (1996). "Evidence for leptin binding to proteins in serum of rodents and humans:modulation with obesity." Diabetes 45 (11):1638-43.
[78]Houten SM, Chegary M, te Brinke H et al (2009) Pyruvate dehydrogenase kinase 4 expression is synergistically induced by AMP-activated protein kinase and fatty acids. Cell Mol Life Sci 66:1283-1294
[79]Howard, J. K., B. J. Cave, et al. (2004). "Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3." Nat Med 10 (7):734-8.
[80]Huang B, Wu P, Bowker-Kinley MM, Harris RA (2002) Regulation of pyruvate dehydrogenase kinase expression by peroxisome proliferator-activated receptor-alpha ligands, glucocorticoids, and insulin. Diabetes 51:276-283
[81]Hue L, Taegtmeyer H (2009) The Randle cycle revisited:a new head for an old hat. Am J Physiol Endocrinol Metab 297:E578-E591
[82]Jan-Jong Hung, Meng-Ti Hsieh, Ming-Jer Young, et al. An External Loop Region of Domain Ⅲ of Dengue Virus Type 2 Envelope Protein Is Involved in Serotype-Specific Binding to Mosquito but Not Mammalian Cells. JOURNAL OF VIROLOGY, Jan.2004, p.378-388
[83]Joazeiro, C. A., S. S. Wing, et al. (1999). "The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase." Science 286 (5438):309-12.
[84]Juliana Helena Chavez, Jaqueline Raymondi Silva, Alberto Anastacio Amarilla, Luiz Tadeu Moraes Figueiredo. Domain Ⅲ peptides from flavivirus envelope protein are useful antigens for serologic diagnosis and targets for immunization. Biologicals 38 (2010) 613-618.
[85]Kamimura, M., C. Viedt, et al. (2005). "lnterleukin-10 suppresses tissue factor expression in lipopolysaccharide-stimulated macrophages via inhibition of Egr-1 and a serum response element/MEK-ERK1/2 pathway." Circ Res 97 (4) 305-13.
[86]Kamura, T., S. Sato, et al. (1998). "The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families." Genes Dev 12 (24):3872-81.
[87]Karnitz, L. M. and R. T. Abraham (1995). "Cytokine receptor signaling mechanisms." Curr Opin Immunol 7 (3):320-6.
[88]Karpati G, Carpenter S, Engel AG et al (1975) The syndrome of systemic carnitine deficiency. Clinical, morphologic, biochemical, and pathophysiologic features. Neurology 25:16-24
[89]Kelly DP, Whelan AJ, Ogden ML et al (1990) Molecular characterization of inherited medium-chain acyl-CoA dehydrogenase deficiency. Proc Natl Acad Sci U S A 87:9236-9240
[90]Kiens B (2006) Skeletal muscle lipid metabolism in exercise and insulin resistance. Physiol Rev 86:205-243
[91]Kim,Y. B., S. Uotani, et al. (2000). "In vivo administration of leptin activates signal transduction directly in insulin-sensitive tissues:overlapping but distinct pathways from insulin. " Endocrinology 141 (7):2328-39.
[92]Krebs, D. L. and D. J. Hilton (2000). "SOCS:physiological suppressors of cytokine signaling." J Cell Sci 113 (Pt 16):2813-9.
[93]Kinjyo, I., T. Hanada, et al. (2002). "SOCS1/JAB is a negative regulator of LPS-induced macrophage activation." Immunity 17 (5):583-91.
[94]Knoop F (1904) Der Abbau aromatischer Fettsauren im Tierkorper. Beitr Chem Physiol Pathol 6:150-162
[95]Knipe, D. M. H and Peter, M. Field Virology.5th ed. vol.1. Lippincott Williams & Wilkins, Pa., USA
[96]Kobayashi, T., G. Takaesu, et al. (2006). "Mal-function of TLRs by SOCS. " Nat Immunol 7 (2):123-4.
[97]Koves TR.Ussher JR.Noland RC et al(2008)Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 7:45-56
[98]Krebs, D. L. and D. J. Hilton (2000). "SOCS:physiological suppressors of cytokine signaling." J Cell Sci 113 (Pt 16):2813-9.
[99]Krey G, Braissant 0, L'Horset F et al (1997) Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 11:779-791
[100]Kubo, M., T. Hanada, et al. (2003). "Suppressors of cytokine signaling and immunity." Nat Immunol 4 (12):1169-76.
[101]Kurtz DM, Rinaldo P, Rhead WJ et al (1998) Targeted disruption of mouse long-chain acyl-CoA dehydrogenase gene reveals crucial roles for fatty acid oxidation. Proc Natl Acad Sci US A95:15592-15597
[102]Laforet P.Vianey-Saban C,Vissing J. (2008).162nd ENMC international workshop: disorders of muscle lipid metabolism in adults 28-30, Bussum, The Netherlands. Neuromuscul Disord 2010; 20:283-9.
[103]Laforet P, Acquaviva-Bourdain C, Rigal 0, et al. Diagnostic assessment and long-term follow-up of 13 patients with very long-chain acyl-coenzyme A dehydrogenase (VLCAD) deficiency. Neuromuscul Disord 2009; 19:324-9.
[104]Laforet P, Vianey-Saban C. (2010) "Disorders of muscle lipid metabolism: diagnostic and therapeutic challenges. " Neuromuscul Disord.; 20 (11) 693-700.
[105]Lagathu, C., J. P. Bastard, et al. (2003). "Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte:prevention by rosiglitazone. " Biochem Biophys Res Commun 311 (2) 372-9.
[106]Lang TF. Adult presentations of medium-chain acyl-CoA dehydrogenase deficiency (MCADD). J Inherit Me tab Dis 2009; 32:675-83.
[107]Lavan, B. E., W. S. Lane, et al. (1997). "The 60-kDa phosphotyrosine protein in insulin-treated adipocytes is a new member of the insulin receptor substrate family." J Biol Chem 272 (17):11439-43.
[108]Le W, Abbas AS, Sprecher H, Vockley J, Schulz H (2000) Long-chain acyl-CoA dehydrogenase is a key enzyme in the mitochondrial beta-oxidation of unsaturated fatty acids. Biochim Biophys Acta 1485:121-128
[109]Lefevre C, Jobard F, Caux F, et al. Mutations in CGI-58, the gene encoding a new protein of the esterase/lipase/thioesterase subfamily, in Chanarin-Dorfman syndrome. Am J Hum Genet 2001; 69:1002-12.
[110]Lehmann, U., J. Schmitz, et al. (2003). "SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130." J Biol Chem 278 (1):661-71.
[111]Li C, Zhang LY, Sun MX, Li PP, Huang L, Wei JC, Yao YL, Isahg H, Chen PY, Mao X. Inhibition of Japanese encephalitis virus entry into the cells by the envelope glycoprotein domain III (EDIII) and the 1oop3 peptide derived from EDIII. Antiviral Res.2012 May; 94 (2):179-83.
[112]Lindberg, K., S. G. Ronn, et al. (2005). "Regulation of pancreatic beta-cell mass and proliferation by SOCS-3." J Mol Endocrinol 35 (2):231-43.
[113]Luca VC, AbiMansour J, Nelson CA, Fremont DH. Crystal structure of the Japanese encephalitis virus envelope protein. J Virol.2012 Feb; 86 (4):2337-46.
[114]Mandard S,Muller M, Kersten S(2004)Peroxisome proliferator activated receptor alpha target genes. Cell Mol Life Sci 61:393-416
[115]Mansell, A., R. Smith, et al. (2006). "Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation." Nat Immunol 7 (2):148-55.
[116]Marine, J. C., C. McKay, et al. (1999). "S OCS3 is essential in the regulation of fetal liver erythropoiesis. " Cell 98 (5):617-27.
[117]Matsubara Y, Narisawa K, Miyabayashi S et al (1990) Identification of a common mutation in patients with medium-chain acyl-CoA dehydrogenase deficiency. Biochem Biophys Res Commun 171:498-505
[118]Matsumoto, A., Y. Seki, et al. (2003). "A role of suppressor of cytokine signaling 3 (SOCS3/CIS3/SSI3) in CD28-mediated interleukin 2 production. " J Exp Med 197 (4):425-36.
[119]Melikova, M. S., M. M. Filatova, et al. (2003)."[Cbl-a polyfunctional regulator of cellular processes]." Tsitologiia 45 (11):1134-48.
[120]Mori, H., R. Hanada, et al. (2004). "Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity." Nat Med 10 (7):739-43.
[121]Murakami K, Ide T, Suzuki M, Mochizuki T, Kadowaki T (1999) Evidence for direct binding of fatty acids and eicosanoids to human peroxisome proliferators-activated receptor alpha. Biochem Biophys Res Commun 260:609-613
[122]Mynatt RL (2009) Carnitine and type 2 diabetes. Diabetes Metab Res Rev 25 (Suppl 1):S45-S49
[123]Naka, T., M. Narazaki, et al. (1997). "Structure and function of a new STAT-induced STAT inhibitor." Nature 387 (6636):924-9.
[124]Nakagawa, R., T. Naka, et al. (2002). "SOCS-1 participates in negative regulation of LPS responses." Immunity 17 (5):677-87.
[125]Nezu J, Tamai I, Oku A, et al. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet 1999; 21:91-4.
[126]Nicholson,S. E.,D. De Souza,et al. (2000). "Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gpl30." Proc Natl Acad Sci U S A 97 (12):6493-8.
[127]Nicholson, S. E., T. A. Willson, et al. (1999). "Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. " Embo J 18 (2):375-85.
[128]Noland RC, Koves TR, Seiler SE et al (2009) Carnitine insufficiency caused by aging and overnutrition compromises mitochondrial performance and metabolic control. J Biol Chem 284:22840-22852
[129]O'Shea, J. J., M. Gadina, et al. (2002). "Cytokine signaling in 2002:new surprises in the Jak/Stat pathway." Cell 109 Suppl:S121-31.
[130]Ohashi Y, Hasegawa Y, Murayama K, et al. A new diagnostic test for VLCAD deficiency using immunohistochemistry. Neurology 2004; 62:2209-13.
[131]Ohh, M., Y. Takagi, et al. (1999). "Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein. " J Clin Invest 104 (11):1583-91.
[132]Ohkuma A, Noguchi S, Sugie H, et al. Clinical and genetic analysis of lipid storage myopathies. Muscle Nerve 2009; 39:33-342.
[133]Ohkuma A, Nonaka I, Malicdan MCV, et al. Distal lipid storage myopathy due to PNPLA2 mutation. Neuromuscul Disord 2008; 18:671-4.
[134]Olpin SE, Clark S, Andresen BS. Bischoff C, et al. Biochemical, clinical and molecular findings in LCHAD and general mitochondrial trifunctional protein deficiency. J Inherit Metab Dis 2005; 28:533-44.
[135]Pedersen CB, K(?)lvraa S, K(?)lvraa A, et al. The ACADS gene variation spectrum in 114 patients with short-chain acyl-CoA dehydrogenase (SCAD) deficiency is dominated by missense variations leading to protein misfolding at the cellular level. Hum Genet 2008; 124:43-56.
[136]Peiser, C., G. P. McGregor, et al. (2000). "Leptin receptor expression and suppressor of cytokine signaling transcript levels in high-fat-fed rats." Life Sci 67 (24):2971-81.
[137]Peraldi, P., C. Filloux, et al. (2001). "Insulin induces suppressor of cytokine signaling-3 tyrosine phosphorylation through janus-activated kinase. " J Biol Chem 276 (27):24614-20.
[138]Pezet, A., H. Favre, et al. (1999). "Inhibition and restoration of prolactin signal transduction by suppressors of cytokine signaling." J Biol Chem 274 (35):24497-502.
[139]Price N, van der Lei j FR, Jackson V et al (2002) A novel brainexpressed protein related to carnitine palmitoyltransferase I. Genomics 80:433-442
[140]Ramsay RR. Gandour RD, van der Lei j FR (2001) Molecular enzymology of carnitine transfer and transport. Biochim Biophys Acta 1546:21-43
[141]Rao, N., I. Dodge, et al. (2002). "The Cbl family of ubiquitin ligases:critical negative regulators of tyrosine kinase signaling in the immune system." J Leukoc Biol 71 (5):753-63.
[142]Rea, S. and D. E. James (1997). "Moving GLUT4:the biogenesis and trafficking of GLUT4 storage vesicles." Diabetes 46 (11):1667-77.
[143]Reinstein, E. (2004). "Immunologic aspects of protein degradation by the ubiquitin-proteasome system."Isr Med Assoc J 6 (7):420-4.
[144]Robert Modre-Osprian, Ingrid Osprian, et al. (2009) "Dynamic simulations on the mitochondrial fatty acid Beta-oxidation network", BMC Systems Biology, 3:2.
[145]Ronn, S. G., J. A. Hansen, et al. (2002). "The effect of suppressor of cytokine signaling 3 on GH signaling in beta-cells.'Mol Endocrinol 16 (9):2124-34.
[146]Rui, L., M. Yuan, et al. (2002). "SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2." J Biol Chem 277 (44) 42394-8.
[147]Ruitenbeek W, Poels PJ, Turnbull DM, et al. Rhabdomyolysis and acute encephalopathy in late onset medium chain acyl-CoA dehydrogenase deficiency. J Neurol Neurosurg Psychiatry 1995; 58:209-14.
[148]Sander Michel Houten. Ronald J. A. Wander. (2010). "A general introduction on the biochemistry of mitochondrail fatty acid β-oxidation" J Inherit Meta Dis 33:469-477)
[149]Schimmenti LA, Crombez EA, Schwahn BC, et al. Expanded newborn screening identifies maternal primary carnitine deficiency. Mol Genet Metab 2007; 90:441-5.
[150]Schaap FG, Binas B, Danneberg H, van der Vusse GJ, Glatz JF (1999) Impaired long-chain fatty acid utilization by cardiac myocytes isolated from mice lacking the heart-type fatty acid binding protein gene. Circ Res 85:329- 337
[151]Schulz H (1994) Regulation of fatty acid oxidation in heart. J Nutr 124:165-171
[152]Soupene E, Kuypers FA (2008) Mammalian long-chain acyl-CoA synthetases. Exp Biol Med (Maywood) 233:507-521
[153]Skeletal muscle pathology. In:Mastaglia FL, Lord Walton of Detchant J. editors. New York:Churchill Livingston; 1992.
[154]Spiekerkoetter U, Bennett MJ, Ben-Zeev B, Strauss AW, Tein I. Peripheral neuropathy, episodic myoglobinuria, and respiratory failure in deficiency of the mitochondrial trifunctional protein. Muscle Nerve 2004; 29:66-72.
[155]Starr, R. and D. J. Hilton (1998). "SOCS:suppressors of cytokine signalling. " Int J Biochem Cell Biol 30 (10):1081-5.
[156]Starr, R., T. A. Willson, et. al. (1997). "A family of cytokine-inducible inhibitors of signalling." Nature 387 (6636):917-21.
[157]Steppan, C. M., J. Wang, et al. (2005). "Activation of SOCS-3 by resistin. " Mol Cell Biol 25 (4):1569-75.
[158]Storline L, Jenkins A, Chisholm D, Pascoe W, Khouri S, Kraegen E. Influence of diary fat composition on development of insulin resistance in rats: relationship to muscle triglyceride and w3 fatty acids in muscle phospholipids. Diabetes 1991; 40:280-9.
[159]Sun, W. H., J. K. Burkholder, et al. (1995). "In vivo cytokine gene transfer by gene gun reduces tumor growth in mice." Proc Natl Acad Sci U S A 92 (7) 2889-93.
[160]Takahashi, Y., N. Carpino, et al. (2003). "SOCS3:an essential regulator of LIF receptor signaling in trophoblast giant cell differentiation. " Embo J 22 (3):372-84.
[161]Tebbutt, N. C., A. S. Giraud, et al. (2002). "Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice." Nat Med 8 (10):1089-97.
[162]Tein I, DeVivo DC, Bierman F, et al. Impaired skin fibroblast carnitine uptake in primary systemic carnitine deficiency manifested by childhood carnitineresponsive cardiomyopathy. Pediatr Res 1990; 28:247-55.
[163]Tein I, Elpeleg O, Ben-Zeev B, et al. Short-chain acyl-CoA dehydrogenase gene mutation (c.319C> T) presents with clinical heterogeneity and is candidate founder mutation in individuals of Ashkenazi Jewish origin. Mol Genet Metab 2008; 93:179-89.
[164]Thongtan T, Wikan N, Wintachai P, Rattanarungsan C, Srisomsap C, Cheepsunthorn P, Smith DR. Characterization of putative Japanese encephalitis virus receptor molecules on microglial cells. J Med Virol.2012 Apr; 84 (4):615-23.
[165]Thuillier L, Rostane H, Droin V, et al. Correlation between genotype, metabolic data, and clinical presentation in carnitine palmitoyltransferase 2 deficiency. Hum Mutat 2003; 5:493-501.
[166]Toshifumi Aoyama, Ichiro Ueno, et al. (1994). "Rat Very-long-chain Acyl-CoA Dehydrogenase, a Novel Mitochondrial Acyl-CoA Dehydrogenase Gene Product, Is a Rate-limiting Enzyme inL ongchain Fatty Acid β-Oxidation System" The Journal of Biological Chemistry. VOl 269, No.29, PP.19088-19094.
[167]Treem WR, Stanley CA, Finegold DN, Hale DE, Coates PM. Primary carnitine deficiency due to a failure of carnitine transport in kidney, muscle, and fibroblasts. N Engl J Med 1988; 319:1331-6.
[168]Tyni T, Majander A, Kalimo H, Rapola J, Pihko H. Pathology of skeletal muscle and impaired respiratory chain function in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency with the G1528C mutation. Neuromuscul Disord 1996; 6:327-37.
[169]Ulrich, H. D. Natural substrates of the proteasome and the recognition by the 20 ubiquitin system, Current Topic Microbiology and Immunology 268 (2002) 137-174.
[170]Van der Leij FR, Huijkman NC, Boomsma C, KuipersJR, Bartelds B (2000) Genomics of the human carnitine acyltransferase genes. Mol Genet Metab 71:139-153
[171]Van Maldegem BT, Duran M, Wanders RJ, Niezen-Koning KE, Hoveveen M, Ijlst L, et al. Clinical, biochemical, and genetic heterogeneity in short-chain acylcoenzyme A dehydrogenase deficiency. JAMA 2006; 296:943-52.
[172]Vianey-Saban C, Divry P, Brivet M, et al. Mitochondrial very-long-chain acylcoenzyme A dehydrogenase deficiency:clinical characteristics and diagnostic considerations in 30 patients. Clin Chim Acta 1998; 269:43-62.
[173]Wanders RJ, Vreken P, den Boer ME, Wijburg FA, van Gennip AH, IJlst L(1999) Disorders of mitochondrial fatty acyl-CoA beta oxidation. J Inherit Metab Dis 22:442-487
[174]Wang,Z., Y. T. Zhou, et al. (2000). "Leptin resistance of adipocytes in obesity: role of suppressors of cytokine signaling." Biochem Biophys Res Commun 277 (1):20-6.
[175]Wang, Z. W., W. T. Pan, et al. (2001). "The role of leptin resistance in the lipid abnormalities of aging." Faseb J 15 (1):108-114.
[176]White, D. W., K. K. Kuropatwinski, et al. (1997). "Leptin receptor (OB-R) signaling. Cytoplasmic domain mutational analysis and evidence for receptor homo-oligomerization. " J Biol Chem 272 (7):4065-71
[177]Wu P, Peters JM, Harris RA (2001) Adaptive increase in pyruvate dehydrogenase kinase 4 during starvation is mediated by peroxisome proliferator-activated receptor alpha. Biochem Biophys Res Commun 287:391-396
[178]Xu HE, Lambert MH, Montana VG et al (1999) Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 3:397-403
[179]Yamamoto, K., M. Yamaguchi, et al. (2003). "SOCS-3 inhibits IL-12-induced STAT4 activation by binding through its SH2 domain to the STAT4 docking site in the IL-12 receptor beta2 subunit." Biochem Biophys Res Commun 310 (4) 1188-93.
[180]Yasukawa, H., M. Ohishi, et al. (2003). "IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. " Nat Immunol 4 (6):551-6.
[181]Yasukawa, H., A. Sasaki, et al. (2000). "Negative regulation of cytokine signaling pathways." Annu Rev Immunol 18:143-64.
[182]Yeh, E. T., L. Gong, et al. (2000). "Ubiquitin-like proteins:new wines in new bottles." Gene 248 (1-2):1-14.
[183]Yoshimura, A..H. Nishinakamura, et al. (2005). "Negative regulation of cytokine signaling and immune responses by SOCS proteins. " Arthritis Res Ther 7 (3) 100-10.
[184]Yu, C. R., R. M. Mahdi, et al. (2003). "Suppressor of cytokine signaling 3 regulates proliferation and activation of T-helper cells." J Biol Chem 278 (32):29752-9.
[185]Zeharia A, Shaag A, Houtkooper RH, et al. Mutations in LPIN1 cause recurrent acute myoglobinuria in childhood. Am J Hum Genet 2008; 83:489-94.
[186]Zhang, Y., R. Proenca, et al. (1994). "Positional cloning of the mouse obese gene and its human homologue. " Nature 372 (6505):425-32.
[187]Zhang, W. et al. Placement of the structural proteins in Sindbis virus. J. Virol.76,11645-11658(2002)
[188]ZhuoWei Wang, WenTong Pan, Young Lee, Tetsuya Kakuma, YanTing Zhou and Roger H. Unger. The role of leptin resistance in the lipid abnormalities of aging, Faseb Journal 15 (2001) 108-114.
[189]Zhuowei Wang, Yan-Ting Zhou, Tetsuya Kakuma, Young Lee, Satya P.21 Kalra. Pushpa S. Kalra, Wentong Pan, and Roger H. Unger. Leptin Resistance of Adipocytes in Obesity:Role of Suppressors of Cytokine Signaling, Biochemical and Biophysical Research Communications 277 (2000) 20-26.
[2]Adams SH, Hoppel CL, Lok KH et al (2009) Plasma acylcarnitine prof iles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women, J Nutr 139:1073-1081
[3]Akiyama M,Sakai K,Ogawa M, McMillan JR,Sawamura D,Shimizu H. Novel duplication mutation in the patatin domain of adipose triglyceride lipase (PNPLA2) in neutral lipid storage disease with severe myopathy. Muscle Nerve 2007; 36:856-9.
[4]Aman, M. J. and W. J. Leonard (1997). "Cytokine signaling:cytokine-inducible signaling inhibitors." Curr Biol 7 (12):R784-8.
[5]Andresen BS, Vianey-Saban C, Bross P, et al. The mutational spectrum in very long-chain acyl-CoA dehydrogenase deficiency. J Inherit Metab Dis 1996; 19:169-72.
[6]Andresen BS, Olpin S, Poorthuis BJHM, et al. Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. Am J Hum Genet 1999; 64:478-94.
[7]Aoyama, T., M. Souri, et al. (1995). "Cloning of human very-long-chain acyl-coenzyme A dehydrogenase and molecular characterization of its deficiency in two patients." Am J Hum Genet 57 (2):273-83.
[8]Aoyama, T.,1. Ueno, et al. (1994). "Rat very-long-chain acyl-CoA dehydrogenase-a novel mitochondrial acyl-CoA dehydrogenase gene product, is a rate-limiting enzyme in long-chain fatty acid beta-oxidation system. cDNA and deduced amino acid sequence and distinct specificities of the cDNA-expressed protein. " J Biol Chem 269 (29):19088-94.
[9]Attoub, S., V. Noe, et al. (2000). "Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, rho-, and rac-dependent signaling pathways." Faseb J 14 (14):2329-38.
[10]Bado, A., S. Levasseur, et al. (1998). "The stomach is a source of leptin. " Nature 394 (6695):790-3.
[11]Baerlocher KE, Steinmann B, Aguzzi A, KraenbOl S, Roe CR, Vianey-Saban C. Short-chain acyl-CoA dehydrogenase deficiency in a 16-year-old girl with severe muscle wasting and scoliosis. J Inher Metab Dis 1997; 20:427-31.
[12]Banerjee, A., A. S. Banks, et al. (2002). "Cutting edge:Suppressor of cytokine signaling 3 inhibits activation of NFATp. " J Immunol 168 (9):4277-81.
[13]Banks, A. S., S. M. Davis, et al. (2000). "Activation of downstream signals by the long form of the leptin receptor." J Biol Chem 275 (19):14563-72.
[14]BartlettK, Eaton S (2004) Mitochondrial beta-oxidation. Eur J Biochem 271:462-469
[15]Ben Ammar A, Petit F, Alexandri N, et al. Phenotype genotype analysis in 15 patients presenting congenital myasthenic syndrome due to mutation in DOK7. J Neurol 2010; 257:754-66.
[16]Binas B, Han XX, Erol E et al (2003) A null mutation in H-FABP only partially inhibits skeletal muscle fatty acid metabolism. Am J Physiol Endocrinol Metab 285:E481-E489
[17]Bjorbaek, C., K. El-Haschimi, et al. (1999). "The role of SOCS-3 in leptin signaling and leptin resistance." J Biol Chem 274 (42):30059-65.
[18]Bjorbaek, C., J. K. Elmquist, et al. (1998). "Identification of SOCS-3 as a potential mediator of central leptin resistance. " Mol Cell 1 (4):619-25.
[19]Bjorbak, C., H. J. Lavery, et al. (2000). "SOCS3 mediates feedback inhibition of the leptin receptor via Tyr985. " J Biol Chem 275 (51):40649-57.
[20]Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J (2004) Carnitine palmitoyltransferases 1 and 2:biochemical, molecular and medical aspects. Mol Aspects Med 25:495-520
[21]Brender, C., P. Lovato, et al. (2005). "Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha. " Leukemia 19 (2) 209-13.
[22]Brivet M, Tubiana S, Boutron A, et al. Transcriptional analysis of HADHA and HADHB genes encoding the mitochondrial trifunctional protein. J Inher Metab Dis 2008; 31:35.
[23]Bruno C, Bertini E, Di Rocco M, et al. Clinical et genetic characterization of Chanarin-Dorfman syndrome. Biochem Biophys Res Commun 2008; 369:1125-8.
[24]Cacalano, N. A., D. Sanden, et al. (2001). "Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras. " Nat Cell Biol 3 (5):460-5.
[25]Campagna F, Nanni L, Quagliarini F. et al. Novel mutations in the adipose triglyceride lipase gene causing neutral lipid storage disease with myopathy. Biochem Biophys Res Commun 2008; 377:843-6.
[26]Chanarin I, Patel A, Slavin G, Wills EJ, Andrews TM. Stewart G. Neutral-lipid
[27]storage disease:a new disorder of lipid metabolism. Br Med J 1975; 1:553-b.
[28]Chegary M, te Brinke H, Ruiter JP et al (2009) Mitochondrial long chain fatty acid beta-oxidation in man and mouse. Biochim Biophys Acta 1791:806-815
[29]Cheng, F., H. W. Wang, et al. (2003). "A critical role for Stat3 signaling in immune tolerance." Immunity 19 (3):425-36.
[30]Ciechanover, A., A, Orian, et al. (2000). "Ubiquitin-mediated proteolysis: biological regulation via destruction. " Bioessays 22 (5):442-51.
[31]Corti S.Bordoni A, Ronchi D, et al. Clinical features and new molecular findings in carnitine palmitoyltransferase Ⅱ (CPTⅡ) deficiency. J Neurol Sci 2008; 266:97-103.
[32]Crespo, A., M. B. Filla, et al. (2000). "Indirect induction of suppressor of cytokine signalling-1 in macrophages stimulated with bacterial lipopolysaccharide:partial role of autocrine/paracrine interferon-alpha/beta." Biochem J 349 (Pt 1):99-104.
[33]Croker, B. A., D. L. Krebs, et al. (2003). "SOCS3 negatively regulates IL-6 signaling in vivo." Nat Immunol 4 (6):540-5.
[34]Czech,M. P. and S. Corvera(1999). "Signaling mechanisms that regulate glucose transport." J Biol Chem 274 (4):1865-8.
[35]Dakin HD (1908) Comparative studies of the mode of oxidation of phenyl derivatives of fatty acids by the animal organism and by hydrogen peroxide, j Biol Chem 4:419-435
[36]Das AM, Fingerhut R, Wanders RJ, Ullrich K. Secondary respiratory chain defect in a boy with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency:possible diagnostic pitfalls. Eur J Pediatr 2000; 159:243-6.
[37]Dariusz Moczulski, Lwona Majak, et al. (2009). " An overview of β-oxidation Disorders". Postepy Hig Med Dosw 63:266-277.
[38]De Souza, D., L. j. Fabri, et al. (2002). "SH2 domains from suppressor of cytokine signaling-3 and protein tyrosine phosphatase SHP-2 have similar binding specificities." Biochemistry 41 (29):9229-36.
[39]Di Donato S, Taroni F. Disorders of lipid metabolism. In:Engel A, editor. Myology. New York:McGraw-Hill Professional Publishing; 2004. p.1587-615.
[40]Dickensheets, H. L., C. Venkataraman, et al. (1999). "Interferons inhibit activation of STAT6 by interleukin 4 in human monocytes by inducing SOCS-1 gene expression." Proc Natl Acad Sci U S A 96 (19):10800-5.
[41]DiMauro S, Melis-DiMauro PM. Muscle carnitine palmitoyltransferase deficiency and myoglobinuria. Science 1973; 182:929-31.
[42]DiMauro S. Papadimitriou A. Carnitine palmitoyl transferase deficiency. In: Engel AG, Banker BQ, editors. Myology. New York:McGraw-Hill; 1986. P.1687-708.
[43]Doege H, Stahl A (2006) Protein-mediated fatty acid uptake:novel insights from in vivo models. Physiology (Bethesda) 21:259-268
[44]Doege H, Baillie RA, Ortegon AM et al (2006) Targeted deletion of FATP5 reveals multiple functions in liver metabolism:alterations in hepatic lipid homeostasis. Gastroenterology 130:1245-1258
[45]Drynan L, Quant PA, Zammit VA (1996) Flux control exerted by mitochondrial outer membrane carnitine palmitoyltransferase over beta-oxidation, ketogenesis and tricarboxylic acid cycle activity in hepatocytes isolated from rats in different metabolic states. Biochem J 317 (Pt 3):791-795
[46]Dunn, S. L., M. Bjornholm, et al. (2005). "Feedback inhibition of leptin receptor/Jak2 signaling via Tyrl138 of the leptin receptor and suppressor of cytokine signaling 3." Mol Endocrinol 19 (4):925-38.
[47]Egwuagu, C. E., C. R. Yu, et al. (2002). "Suppressors of cytokine signaling proteins are differentially expressed in Thl and Th2 cells:implications for Th cell lineage commitment and maintenance." J Immunol 168 (7):3181-7.
[48]Emanuelli, B., M. Glondu, et al. (2004). "The potential role of SOCS-3 in the interleukin-lbeta-induced desensitization of insulin signaling in pancreatic beta-cells." Diabetes 53 Suppl 3:S97-S103.
[49]Emanuelli, B., P. Peraldi, et al. (2000). "SOCS-3 is an insulin-induced negative regulator of insulin signaling." J Biol Chem 275 (21):15985-91.
[50]Endo, T. A., M. Masuhara, et al. (1997). "A new protein containing an SH2 domain that inhibits JAK kinases. " Nature 387 (6636):921-4.
[51]Engel AC, Angelini C. Carnitine deficiency of human skeletal muscle with associated lipid storage myopathy. A new syndrome. Science 1973; 179:899-902.
[52]Ensenauer R, He M, Willard JM et al (2005) Human acyl-CoA dehydrogenase-9 plays a novel role in the mitochondrial betaoxidation of unsaturated fatty acids. J Biol Chem 280:32309-32316
[53]Erol E, Kumar LS, Cline GW, Shulman GI, Kelly DP, Binas B (2004) Liver fatty acid binding protein is required for high rates of hepatic fatty acid oxidation but not for the action of PPARa lpha in fasting mice. FASEB J 18:347-349
[54]Fischer J, Lefevre C, Morava E, et al. The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy. Nat Genet 2007; 39:28-30.
[55]Forman BM, Chen J, Evans RM (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 94:4312-4317
[56]Fujimoto, M. and T. Naka (2003). "Regulation of cytokine signaling by SOCS family molecules." Trends Immunol 24 (12):659-66.
[57]Fritz IB (1955) The effect of muscle extracts on the oxidation of palmitic acid by liver slices and homogenates. Acta Physiol Scand 34:367-385
[58]Fritz IB, McEwen B(1959) Effects of carnitine on fatty-acid oxidation by muscle. Science 129:334-335
[59]Furuta S, Miyazawa S, Hashimoto T (1981) Purification and properties of rat liver acyl-CoA dehydrogenases and electron transfer flavoprotein. J Biochem 90:1739-1750
[60]Gimeno RE, OrtegonAM, Patel S et al (2003) Characterization of a heartspec if ic fatty acid transport protein. J Biol Chem 278:16039-16044
[61]Giordanetto, F. and R. T. Kroemer (2003). "A three-dimensional model of Suppressor Of Cytokine Signalling 1 (SOCS-1)." Protein Eng 16 (2):115-24.
[62]Glatz JF, Bonen A, Ouwens DM, Luiken JJ (2006) Regulation of sarcolemmal transport of substrates in the healthy and diseased heart. Cardiovasc Drugs Ther 20:471-476
[63]Goodpaster BH, Thaete FL, Simoneau JA, Kelley DE. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 1997; 46:1579-85.
[64]Gregersen N, Bross P, Andresen BS:Genetic defects in fatty acid beta-oxidation and acyl-CoA dehydrogenases. Molecular pathogenesis and genotype-phenotype relationships. Eur JBiochem 2004,271:470-482.
[65]Gregersen N, Andresen BS, Pedersen CB, Olsen RK, Corydon TJ, Bross P. Mitochondrial fatty acid oxidation defects-remaining challenges. J Inherit Metab Dis 2008; 31:643-57.
[66]Gylvin, T., R. Nolsoe, et al. (2004). "Mutation analysis of suppressor of cytokine signalling 3, a candidate gene in Type 1 diabetes and insulin sensitivity." Diabetologia 47 (7):1273-7.
[67]Hashimoto, C., K. L. Hudson, et al. (1988). "The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein." Cell 52 (2):269-79.
[68]He,B.,L. You, et al. (2003). "SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer." Proc Natl Acad Sci U S A 100 (24):14133-8.
[69]He, B., L. You, et al. (2004). "Activity of the suppressor of cytokine signal ing-3 promoter in human non-small-cell lung cancer." Clin Lung Cancer 5 (6):366-70.
[70]Helge JW, Stallknecht B, Richter EA, Galbo H, Kiens B (2007) Muscle metabolism during graded quadriceps exercise in man. J Physiol 581:1247-1258
[71]Hershko, A., A. Ciechanover, et al. (2000). "Basic Medical Research Award. The ubiquitin system." Nat Med 6 (10):1073-81.
[72]Hilton, D. J., R. T. Richardson, et al. (1998). "Twenty proteins containing a C-terminal SOCS box form five structural classes." Proc Natl Acad Sci U S A 95 (1):114-9.
[73]Hirano, T., T. Taga, et al. (1985). "Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). " Proc Natl Acad Sci U S A 82 (16):5490-4.
[74]Holler, D. and I. Dikic(2004). "Receptor endocytosis via ubiquitin-dependent and -independent pathways." Biochem Pharmacol 67 (6):1013-7.
[75]Hortner, M., U. Nielsch, et al. (2002). "A new high affinity binding site for suppressor of cytokine signal ing-3 on the erythropoietin receptor. " Eur J Biochem 269 (10):2516-26.
[76]Houseknecht, K. L., C. A. Baile, et al. (1998). "The biology of leptin:a review." J Anim Sci 76 (5):1405-20.
[77]Houseknecht, K. L., C. S. Mantzoros, et al. (1996). "Evidence for leptin binding to proteins in serum of rodents and humans:modulation with obesity." Diabetes 45 (11):1638-43.
[78]Houten SM, Chegary M, te Brinke H et al (2009) Pyruvate dehydrogenase kinase 4 expression is synergistically induced by AMP-activated protein kinase and fatty acids. Cell Mol Life Sci 66:1283-1294
[79]Howard, J. K., B. J. Cave, et al. (2004). "Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3." Nat Med 10 (7):734-8.
[80]Huang B, Wu P, Bowker-Kinley MM, Harris RA (2002) Regulation of pyruvate dehydrogenase kinase expression by peroxisome proliferator-activated receptor-alpha ligands, glucocorticoids, and insulin. Diabetes 51:276-283
[81]Hue L, Taegtmeyer H (2009) The Randle cycle revisited:a new head for an old hat. Am J Physiol Endocrinol Metab 297:E578-E591
[82]Jan-Jong Hung, Meng-Ti Hsieh, Ming-Jer Young, et al. An External Loop Region of Domain Ⅲ of Dengue Virus Type 2 Envelope Protein Is Involved in Serotype-Specific Binding to Mosquito but Not Mammalian Cells. JOURNAL OF VIROLOGY, Jan.2004, p.378-388
[83]Joazeiro, C. A., S. S. Wing, et al. (1999). "The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase." Science 286 (5438):309-12.
[84]Juliana Helena Chavez, Jaqueline Raymondi Silva, Alberto Anastacio Amarilla, Luiz Tadeu Moraes Figueiredo. Domain Ⅲ peptides from flavivirus envelope protein are useful antigens for serologic diagnosis and targets for immunization. Biologicals 38 (2010) 613-618.
[85]Kamimura, M., C. Viedt, et al. (2005). "lnterleukin-10 suppresses tissue factor expression in lipopolysaccharide-stimulated macrophages via inhibition of Egr-1 and a serum response element/MEK-ERK1/2 pathway." Circ Res 97 (4) 305-13.
[86]Kamura, T., S. Sato, et al. (1998). "The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families." Genes Dev 12 (24):3872-81.
[87]Karnitz, L. M. and R. T. Abraham (1995). "Cytokine receptor signaling mechanisms." Curr Opin Immunol 7 (3):320-6.
[88]Karpati G, Carpenter S, Engel AG et al (1975) The syndrome of systemic carnitine deficiency. Clinical, morphologic, biochemical, and pathophysiologic features. Neurology 25:16-24
[89]Kelly DP, Whelan AJ, Ogden ML et al (1990) Molecular characterization of inherited medium-chain acyl-CoA dehydrogenase deficiency. Proc Natl Acad Sci U S A 87:9236-9240
[90]Kiens B (2006) Skeletal muscle lipid metabolism in exercise and insulin resistance. Physiol Rev 86:205-243
[91]Kim,Y. B., S. Uotani, et al. (2000). "In vivo administration of leptin activates signal transduction directly in insulin-sensitive tissues:overlapping but distinct pathways from insulin. " Endocrinology 141 (7):2328-39.
[92]Krebs, D. L. and D. J. Hilton (2000). "SOCS:physiological suppressors of cytokine signaling." J Cell Sci 113 (Pt 16):2813-9.
[93]Kinjyo, I., T. Hanada, et al. (2002). "SOCS1/JAB is a negative regulator of LPS-induced macrophage activation." Immunity 17 (5):583-91.
[94]Knoop F (1904) Der Abbau aromatischer Fettsauren im Tierkorper. Beitr Chem Physiol Pathol 6:150-162
[95]Knipe, D. M. H and Peter, M. Field Virology.5th ed. vol.1. Lippincott Williams & Wilkins, Pa., USA
[96]Kobayashi, T., G. Takaesu, et al. (2006). "Mal-function of TLRs by SOCS. " Nat Immunol 7 (2):123-4.
[97]Koves TR.Ussher JR.Noland RC et al(2008)Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 7:45-56
[98]Krebs, D. L. and D. J. Hilton (2000). "SOCS:physiological suppressors of cytokine signaling." J Cell Sci 113 (Pt 16):2813-9.
[99]Krey G, Braissant 0, L'Horset F et al (1997) Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 11:779-791
[100]Kubo, M., T. Hanada, et al. (2003). "Suppressors of cytokine signaling and immunity." Nat Immunol 4 (12):1169-76.
[101]Kurtz DM, Rinaldo P, Rhead WJ et al (1998) Targeted disruption of mouse long-chain acyl-CoA dehydrogenase gene reveals crucial roles for fatty acid oxidation. Proc Natl Acad Sci US A95:15592-15597
[102]Laforet P.Vianey-Saban C,Vissing J. (2008).162nd ENMC international workshop: disorders of muscle lipid metabolism in adults 28-30, Bussum, The Netherlands. Neuromuscul Disord 2010; 20:283-9.
[103]Laforet P, Acquaviva-Bourdain C, Rigal 0, et al. Diagnostic assessment and long-term follow-up of 13 patients with very long-chain acyl-coenzyme A dehydrogenase (VLCAD) deficiency. Neuromuscul Disord 2009; 19:324-9.
[104]Laforet P, Vianey-Saban C. (2010) "Disorders of muscle lipid metabolism: diagnostic and therapeutic challenges. " Neuromuscul Disord.; 20 (11) 693-700.
[105]Lagathu, C., J. P. Bastard, et al. (2003). "Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte:prevention by rosiglitazone. " Biochem Biophys Res Commun 311 (2) 372-9.
[106]Lang TF. Adult presentations of medium-chain acyl-CoA dehydrogenase deficiency (MCADD). J Inherit Me tab Dis 2009; 32:675-83.
[107]Lavan, B. E., W. S. Lane, et al. (1997). "The 60-kDa phosphotyrosine protein in insulin-treated adipocytes is a new member of the insulin receptor substrate family." J Biol Chem 272 (17):11439-43.
[108]Le W, Abbas AS, Sprecher H, Vockley J, Schulz H (2000) Long-chain acyl-CoA dehydrogenase is a key enzyme in the mitochondrial beta-oxidation of unsaturated fatty acids. Biochim Biophys Acta 1485:121-128
[109]Lefevre C, Jobard F, Caux F, et al. Mutations in CGI-58, the gene encoding a new protein of the esterase/lipase/thioesterase subfamily, in Chanarin-Dorfman syndrome. Am J Hum Genet 2001; 69:1002-12.
[110]Lehmann, U., J. Schmitz, et al. (2003). "SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130." J Biol Chem 278 (1):661-71.
[111]Li C, Zhang LY, Sun MX, Li PP, Huang L, Wei JC, Yao YL, Isahg H, Chen PY, Mao X. Inhibition of Japanese encephalitis virus entry into the cells by the envelope glycoprotein domain III (EDIII) and the 1oop3 peptide derived from EDIII. Antiviral Res.2012 May; 94 (2):179-83.
[112]Lindberg, K., S. G. Ronn, et al. (2005). "Regulation of pancreatic beta-cell mass and proliferation by SOCS-3." J Mol Endocrinol 35 (2):231-43.
[113]Luca VC, AbiMansour J, Nelson CA, Fremont DH. Crystal structure of the Japanese encephalitis virus envelope protein. J Virol.2012 Feb; 86 (4):2337-46.
[114]Mandard S,Muller M, Kersten S(2004)Peroxisome proliferator activated receptor alpha target genes. Cell Mol Life Sci 61:393-416
[115]Mansell, A., R. Smith, et al. (2006). "Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation." Nat Immunol 7 (2):148-55.
[116]Marine, J. C., C. McKay, et al. (1999). "S OCS3 is essential in the regulation of fetal liver erythropoiesis. " Cell 98 (5):617-27.
[117]Matsubara Y, Narisawa K, Miyabayashi S et al (1990) Identification of a common mutation in patients with medium-chain acyl-CoA dehydrogenase deficiency. Biochem Biophys Res Commun 171:498-505
[118]Matsumoto, A., Y. Seki, et al. (2003). "A role of suppressor of cytokine signaling 3 (SOCS3/CIS3/SSI3) in CD28-mediated interleukin 2 production. " J Exp Med 197 (4):425-36.
[119]Melikova, M. S., M. M. Filatova, et al. (2003)."[Cbl-a polyfunctional regulator of cellular processes]." Tsitologiia 45 (11):1134-48.
[120]Mori, H., R. Hanada, et al. (2004). "Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity." Nat Med 10 (7):739-43.
[121]Murakami K, Ide T, Suzuki M, Mochizuki T, Kadowaki T (1999) Evidence for direct binding of fatty acids and eicosanoids to human peroxisome proliferators-activated receptor alpha. Biochem Biophys Res Commun 260:609-613
[122]Mynatt RL (2009) Carnitine and type 2 diabetes. Diabetes Metab Res Rev 25 (Suppl 1):S45-S49
[123]Naka, T., M. Narazaki, et al. (1997). "Structure and function of a new STAT-induced STAT inhibitor." Nature 387 (6636):924-9.
[124]Nakagawa, R., T. Naka, et al. (2002). "SOCS-1 participates in negative regulation of LPS responses." Immunity 17 (5):677-87.
[125]Nezu J, Tamai I, Oku A, et al. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet 1999; 21:91-4.
[126]Nicholson,S. E.,D. De Souza,et al. (2000). "Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gpl30." Proc Natl Acad Sci U S A 97 (12):6493-8.
[127]Nicholson, S. E., T. A. Willson, et al. (1999). "Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. " Embo J 18 (2):375-85.
[128]Noland RC, Koves TR, Seiler SE et al (2009) Carnitine insufficiency caused by aging and overnutrition compromises mitochondrial performance and metabolic control. J Biol Chem 284:22840-22852
[129]O'Shea, J. J., M. Gadina, et al. (2002). "Cytokine signaling in 2002:new surprises in the Jak/Stat pathway." Cell 109 Suppl:S121-31.
[130]Ohashi Y, Hasegawa Y, Murayama K, et al. A new diagnostic test for VLCAD deficiency using immunohistochemistry. Neurology 2004; 62:2209-13.
[131]Ohh, M., Y. Takagi, et al. (1999). "Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein. " J Clin Invest 104 (11):1583-91.
[132]Ohkuma A, Noguchi S, Sugie H, et al. Clinical and genetic analysis of lipid storage myopathies. Muscle Nerve 2009; 39:33-342.
[133]Ohkuma A, Nonaka I, Malicdan MCV, et al. Distal lipid storage myopathy due to PNPLA2 mutation. Neuromuscul Disord 2008; 18:671-4.
[134]Olpin SE, Clark S, Andresen BS. Bischoff C, et al. Biochemical, clinical and molecular findings in LCHAD and general mitochondrial trifunctional protein deficiency. J Inherit Metab Dis 2005; 28:533-44.
[135]Pedersen CB, K(?)lvraa S, K(?)lvraa A, et al. The ACADS gene variation spectrum in 114 patients with short-chain acyl-CoA dehydrogenase (SCAD) deficiency is dominated by missense variations leading to protein misfolding at the cellular level. Hum Genet 2008; 124:43-56.
[136]Peiser, C., G. P. McGregor, et al. (2000). "Leptin receptor expression and suppressor of cytokine signaling transcript levels in high-fat-fed rats." Life Sci 67 (24):2971-81.
[137]Peraldi, P., C. Filloux, et al. (2001). "Insulin induces suppressor of cytokine signaling-3 tyrosine phosphorylation through janus-activated kinase. " J Biol Chem 276 (27):24614-20.
[138]Pezet, A., H. Favre, et al. (1999). "Inhibition and restoration of prolactin signal transduction by suppressors of cytokine signaling." J Biol Chem 274 (35):24497-502.
[139]Price N, van der Lei j FR, Jackson V et al (2002) A novel brainexpressed protein related to carnitine palmitoyltransferase I. Genomics 80:433-442
[140]Ramsay RR. Gandour RD, van der Lei j FR (2001) Molecular enzymology of carnitine transfer and transport. Biochim Biophys Acta 1546:21-43
[141]Rao, N., I. Dodge, et al. (2002). "The Cbl family of ubiquitin ligases:critical negative regulators of tyrosine kinase signaling in the immune system." J Leukoc Biol 71 (5):753-63.
[142]Rea, S. and D. E. James (1997). "Moving GLUT4:the biogenesis and trafficking of GLUT4 storage vesicles." Diabetes 46 (11):1667-77.
[143]Reinstein, E. (2004). "Immunologic aspects of protein degradation by the ubiquitin-proteasome system."Isr Med Assoc J 6 (7):420-4.
[144]Robert Modre-Osprian, Ingrid Osprian, et al. (2009) "Dynamic simulations on the mitochondrial fatty acid Beta-oxidation network", BMC Systems Biology, 3:2.
[145]Ronn, S. G., J. A. Hansen, et al. (2002). "The effect of suppressor of cytokine signaling 3 on GH signaling in beta-cells.'Mol Endocrinol 16 (9):2124-34.
[146]Rui, L., M. Yuan, et al. (2002). "SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2." J Biol Chem 277 (44) 42394-8.
[147]Ruitenbeek W, Poels PJ, Turnbull DM, et al. Rhabdomyolysis and acute encephalopathy in late onset medium chain acyl-CoA dehydrogenase deficiency. J Neurol Neurosurg Psychiatry 1995; 58:209-14.
[148]Sander Michel Houten. Ronald J. A. Wander. (2010). "A general introduction on the biochemistry of mitochondrail fatty acid β-oxidation" J Inherit Meta Dis 33:469-477)
[149]Schimmenti LA, Crombez EA, Schwahn BC, et al. Expanded newborn screening identifies maternal primary carnitine deficiency. Mol Genet Metab 2007; 90:441-5.
[150]Schaap FG, Binas B, Danneberg H, van der Vusse GJ, Glatz JF (1999) Impaired long-chain fatty acid utilization by cardiac myocytes isolated from mice lacking the heart-type fatty acid binding protein gene. Circ Res 85:329- 337
[151]Schulz H (1994) Regulation of fatty acid oxidation in heart. J Nutr 124:165-171
[152]Soupene E, Kuypers FA (2008) Mammalian long-chain acyl-CoA synthetases. Exp Biol Med (Maywood) 233:507-521
[153]Skeletal muscle pathology. In:Mastaglia FL, Lord Walton of Detchant J. editors. New York:Churchill Livingston; 1992.
[154]Spiekerkoetter U, Bennett MJ, Ben-Zeev B, Strauss AW, Tein I. Peripheral neuropathy, episodic myoglobinuria, and respiratory failure in deficiency of the mitochondrial trifunctional protein. Muscle Nerve 2004; 29:66-72.
[155]Starr, R. and D. J. Hilton (1998). "SOCS:suppressors of cytokine signalling. " Int J Biochem Cell Biol 30 (10):1081-5.
[156]Starr, R., T. A. Willson, et. al. (1997). "A family of cytokine-inducible inhibitors of signalling." Nature 387 (6636):917-21.
[157]Steppan, C. M., J. Wang, et al. (2005). "Activation of SOCS-3 by resistin. " Mol Cell Biol 25 (4):1569-75.
[158]Storline L, Jenkins A, Chisholm D, Pascoe W, Khouri S, Kraegen E. Influence of diary fat composition on development of insulin resistance in rats: relationship to muscle triglyceride and w3 fatty acids in muscle phospholipids. Diabetes 1991; 40:280-9.
[159]Sun, W. H., J. K. Burkholder, et al. (1995). "In vivo cytokine gene transfer by gene gun reduces tumor growth in mice." Proc Natl Acad Sci U S A 92 (7) 2889-93.
[160]Takahashi, Y., N. Carpino, et al. (2003). "SOCS3:an essential regulator of LIF receptor signaling in trophoblast giant cell differentiation. " Embo J 22 (3):372-84.
[161]Tebbutt, N. C., A. S. Giraud, et al. (2002). "Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice." Nat Med 8 (10):1089-97.
[162]Tein I, DeVivo DC, Bierman F, et al. Impaired skin fibroblast carnitine uptake in primary systemic carnitine deficiency manifested by childhood carnitineresponsive cardiomyopathy. Pediatr Res 1990; 28:247-55.
[163]Tein I, Elpeleg O, Ben-Zeev B, et al. Short-chain acyl-CoA dehydrogenase gene mutation (c.319C> T) presents with clinical heterogeneity and is candidate founder mutation in individuals of Ashkenazi Jewish origin. Mol Genet Metab 2008; 93:179-89.
[164]Thongtan T, Wikan N, Wintachai P, Rattanarungsan C, Srisomsap C, Cheepsunthorn P, Smith DR. Characterization of putative Japanese encephalitis virus receptor molecules on microglial cells. J Med Virol.2012 Apr; 84 (4):615-23.
[165]Thuillier L, Rostane H, Droin V, et al. Correlation between genotype, metabolic data, and clinical presentation in carnitine palmitoyltransferase 2 deficiency. Hum Mutat 2003; 5:493-501.
[166]Toshifumi Aoyama, Ichiro Ueno, et al. (1994). "Rat Very-long-chain Acyl-CoA Dehydrogenase, a Novel Mitochondrial Acyl-CoA Dehydrogenase Gene Product, Is a Rate-limiting Enzyme inL ongchain Fatty Acid β-Oxidation System" The Journal of Biological Chemistry. VOl 269, No.29, PP.19088-19094.
[167]Treem WR, Stanley CA, Finegold DN, Hale DE, Coates PM. Primary carnitine deficiency due to a failure of carnitine transport in kidney, muscle, and fibroblasts. N Engl J Med 1988; 319:1331-6.
[168]Tyni T, Majander A, Kalimo H, Rapola J, Pihko H. Pathology of skeletal muscle and impaired respiratory chain function in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency with the G1528C mutation. Neuromuscul Disord 1996; 6:327-37.
[169]Ulrich, H. D. Natural substrates of the proteasome and the recognition by the 20 ubiquitin system, Current Topic Microbiology and Immunology 268 (2002) 137-174.
[170]Van der Leij FR, Huijkman NC, Boomsma C, KuipersJR, Bartelds B (2000) Genomics of the human carnitine acyltransferase genes. Mol Genet Metab 71:139-153
[171]Van Maldegem BT, Duran M, Wanders RJ, Niezen-Koning KE, Hoveveen M, Ijlst L, et al. Clinical, biochemical, and genetic heterogeneity in short-chain acylcoenzyme A dehydrogenase deficiency. JAMA 2006; 296:943-52.
[172]Vianey-Saban C, Divry P, Brivet M, et al. Mitochondrial very-long-chain acylcoenzyme A dehydrogenase deficiency:clinical characteristics and diagnostic considerations in 30 patients. Clin Chim Acta 1998; 269:43-62.
[173]Wanders RJ, Vreken P, den Boer ME, Wijburg FA, van Gennip AH, IJlst L(1999) Disorders of mitochondrial fatty acyl-CoA beta oxidation. J Inherit Metab Dis 22:442-487
[174]Wang,Z., Y. T. Zhou, et al. (2000). "Leptin resistance of adipocytes in obesity: role of suppressors of cytokine signaling." Biochem Biophys Res Commun 277 (1):20-6.
[175]Wang, Z. W., W. T. Pan, et al. (2001). "The role of leptin resistance in the lipid abnormalities of aging." Faseb J 15 (1):108-114.
[176]White, D. W., K. K. Kuropatwinski, et al. (1997). "Leptin receptor (OB-R) signaling. Cytoplasmic domain mutational analysis and evidence for receptor homo-oligomerization. " J Biol Chem 272 (7):4065-71
[177]Wu P, Peters JM, Harris RA (2001) Adaptive increase in pyruvate dehydrogenase kinase 4 during starvation is mediated by peroxisome proliferator-activated receptor alpha. Biochem Biophys Res Commun 287:391-396
[178]Xu HE, Lambert MH, Montana VG et al (1999) Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 3:397-403
[179]Yamamoto, K., M. Yamaguchi, et al. (2003). "SOCS-3 inhibits IL-12-induced STAT4 activation by binding through its SH2 domain to the STAT4 docking site in the IL-12 receptor beta2 subunit." Biochem Biophys Res Commun 310 (4) 1188-93.
[180]Yasukawa, H., M. Ohishi, et al. (2003). "IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. " Nat Immunol 4 (6):551-6.
[181]Yasukawa, H., A. Sasaki, et al. (2000). "Negative regulation of cytokine signaling pathways." Annu Rev Immunol 18:143-64.
[182]Yeh, E. T., L. Gong, et al. (2000). "Ubiquitin-like proteins:new wines in new bottles." Gene 248 (1-2):1-14.
[183]Yoshimura, A..H. Nishinakamura, et al. (2005). "Negative regulation of cytokine signaling and immune responses by SOCS proteins. " Arthritis Res Ther 7 (3) 100-10.
[184]Yu, C. R., R. M. Mahdi, et al. (2003). "Suppressor of cytokine signaling 3 regulates proliferation and activation of T-helper cells." J Biol Chem 278 (32):29752-9.
[185]Zeharia A, Shaag A, Houtkooper RH, et al. Mutations in LPIN1 cause recurrent acute myoglobinuria in childhood. Am J Hum Genet 2008; 83:489-94.
[186]Zhang, Y., R. Proenca, et al. (1994). "Positional cloning of the mouse obese gene and its human homologue. " Nature 372 (6505):425-32.
[187]Zhang, W. et al. Placement of the structural proteins in Sindbis virus. J. Virol.76,11645-11658(2002)
[188]ZhuoWei Wang, WenTong Pan, Young Lee, Tetsuya Kakuma, YanTing Zhou and Roger H. Unger. The role of leptin resistance in the lipid abnormalities of aging, Faseb Journal 15 (2001) 108-114.
[189]Zhuowei Wang, Yan-Ting Zhou, Tetsuya Kakuma, Young Lee, Satya P.21 Kalra. Pushpa S. Kalra, Wentong Pan, and Roger H. Unger. Leptin Resistance of Adipocytes in Obesity:Role of Suppressors of Cytokine Signaling, Biochemical and Biophysical Research Communications 277 (2000) 20-26.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |